Med-X,Inc.MXRX IPO Stocks Price,News,Date& information


Company Description

Currently, Med-X’s main line of business is the distribution of environmentally friendly health and wellness products to a variety of markets, including but not limited to the professional pest control sector, over-the-counter pharmacies through distribution partnerships, and consumers directly.

We want to be known as a health and wellness firm that provides other businesses and customers who want to lessen exposure to toxins and chemicals in their homes and communities with a range of natural “green” products and service standards.

A $7 million IPO’s proposed terms have been submitted by Med-X.
The business offers cream for discomfort, heating and cooling packs, and natural pesticides.

MED-X date

The IPO for MXRX will occur on June 21 on the NASDAQ platform under the ticker MXRX.

A 180-day insider lock-up period that will conclude on December 18, 2023, is being offered by the corporation with shares expected to be offered at a price of $4.00 per share.

Med-X, Inc. Information

MXRX is a small business with low sales, significant operating losses, and cash burn.
The company is highly speculative, therefore even while the cheap nominal price of the shares may draw day traders looking for volatility, I’m on Hold for it.
Looking for additional suggestions for investments like this one? Purchase them just at IPO Edge.

Med-X, Inc. Details:

CountryUnited States
IPO DateJun 21, 2023
IndustryHealth Care
CEOMatthew Mills

MXRX IPO full details:

Market Cap21.49M
Revenue (ttm)1.04M
Net Income (ttm)-5.60M
Shares Out5.37M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day’s Rangen/a
52-Week Rangen/a
Price Targetn/a
Earnings Daten/a

Contact Details

Address:8236 Remmet Avenue
Canoga Park, CA 91304
United States
Phone(818) 349-2870

Stock Details

Ticker SymbolMXRX
Fiscal YearJanuary – December
Reporting CurrencyUSD
IPO Price$4.00
CIK Code0001620704
Employer ID46-5473113
SIC Code2834

Key Executives

Dr. David E. ToomeyChief Science Officer
Matthew A. MillsChairman of the Board and Chief Executive Officer
Ronald J. TchorzewskiDirector and Chief Financial Officer
Jennifer J. MillsDirector, President and Corporate Secretary
Nick PhillipsChief Media Officer
Dr. Morton I. HysonDirector
Dr. Allan KurtzDirector
Fred Dashiell, Jr.Director
Michael KuntzDirector
Dennis KemmesatDirector

Income Statement (Annual)

Millions USD. Fiscal year is Jan – Dec.

Revenue Growth (YoY)-2.26%
Cost of Revenue0.880.87
Gross Profit0.130.16
Selling, General & Admin2.151.63
Other Operating Expenses3.212.07
Operating Expenses5.363.69
Operating Income-5.23-3.53
Interest Expense / Income-00.01
Other Expense / Income-0.32
Pretax Income-4.91-3.54
Net Income-4.91-3.54
Gross Margin12.94%15.79%
Operating Margin-517.47%-341.60%
Profit Margin-485.68%-342.54%
Free Cash Flow Margin-440.57%-319.75%
EBITDA Margin-480.59%-330.68%
Depreciation & Amortization0.050.11
EBIT Margin-485.84%-341.60%

Balance Sheet (Annual)

Millions USD. Fiscal year is Jan – Dec.

Cash & Equivalents1.370.75
Cash & Cash Equivalents1.370.75
Cash Growth81.63%
Other Current Assets0.240.1
Total Current Assets2.651.76
Property, Plant & Equipment0.090.08
Goodwill and Intangibles1.071.33
Total Long-Term Assets1.161.41
Total Assets3.823.17
Accounts Payable0.460.49
Current Debt0.260.59
Total Current Liabilities0.711.08
Long-Term Debt0.951.16
Total Long-Term Liabilities0.951.16
Total Liabilities1.662.23
Total Debt1.211.74
Debt Growth-30.91%
Common Stock19.2213.09
Retained Earnings-17.07-12.16
Shareholders’ Equity2.150.93
Net Cash / Debt0.16-0.99
Working Capital1.940.68

Cash Flow Statement (Annual)

Millions USD. Fiscal year is Jan – Dec.

Net Income-4.91-3.54
Depreciation & Amortization0.050.11
Share-Based Compensation1.010.36
Other Operating Activities-0.57-0.23
Operating Cash Flow-4.41-3.3
Capital Expenditures-0.04-0
Other Investing Activities0.04
Investing Cash Flow-0-0
Share Issuance / Repurchase5.123.53
Debt Issued / Paid-0.090.31
Financing Cash Flow5.033.83
Net Cash Flow0.610.53
Free Cash Flow-4.45-3.31
Free Cash Flow Margin-440.57%-319.75%

Ratios and Metrics (Annual)

Millions USD. Fiscal year is Jan – Dec.

Market Capitalization21
Enterprise Value22
Debt / Equity Ratio0.770.561.87
Debt / EBITDA Ratio-0.15-0.25-0.51
Debt / FCF Ratio-0.21-0.27-0.53
Quick Ratio1.871.960.84
Interest Coverage-5699.21-362.89

Total Valuation

Med-X has a market cap or net worth of $21.49 million. The enterprise value is $22.03 million.

Market Cap21.49M
Enterprise Value22.03M

Important Dates

Earnings Daten/a
Ex-Dividend Daten/a

Share Statistics

Med-X has 5.37 million shares outstanding.

Shares Outstanding5.37M
Shares Change (YoY)n/a
Shares Change (QoQ)n/a
Owned by Insiders (%)n/a
Owned by Institutions (%)n/a

Valuation Ratios

PE Ration/a
Forward PEn/a
PS Ratio20.76
Forward PSn/a
PB Ratio14.33
P/FCF Ration/a
PEG Ration/a

Income Statement of med-x

In the last 12 months, Med-X had revenue of $1.04 million and -$5.60 million in losses. Loss per share was -$1.04.

Gross Profit225,063
Operating Income-7.57M
Pretax Income-7.58M
Net Income-5.60M
Loss Per Share-$1.04


What is the stock symbol for Med X?

V – MedX Health Corp

What is stock in medicine?

1.1 The registered nurse/midwife in charge along with appropriate Medical and Pharmacy Staff will agree a list of medicines which will be stocked in the ward/department at all times and these will be termed “stock” medicines

Are medical stocks a good investment?

Many health care stocks offer investors stability and profitability in both good times and bad. But the sector is not without risks — particularly when the government is involved

Med-X, Inc. Stock price

Med-X, Inc. Stock price will be in dollar

Leave a Reply

Your email address will not be published. Required fields are marked *